top of page
Dynamic Drug Advancement Limited | Durham Institute of Respirology
About the Trial
A 26-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Efficacy, Safety, and Tolerability of Axatilimab in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
Mechanism of Action:
Anti-CSF-1R
Duration of Study
26 weeks
Phase
2
Principal Investigator
Dr. George Philteos
Sub-Investigator
Dr. Anushya Chelvnathan
Study Coordinator
Asvini Kulasingham
bottom of page